Brian Thomas, Metagenomi CEO

No in­tro­duc­tions nec­es­sary: A TCR up­start with deep-pock­et back­ers part­ners with one of the new play­ers in the hot gene edit­ing field

When Affi­ni-T ar­rived on the scene a few weeks ago, it had most of the es­sen­tial el­e­ments need­ed by any biotech up­start.

There were high …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.